Publications by authors named "M Lorrot"
Objectives: Children on extracorporeal membrane oxygenation (ECMO) are at high risk of infection that may worsen prognosis. Even though treatment with beta-lactam antibiotics is frequent, dosing is not adapted to altered pharmacokinetic and pharmacodynamic characteristics of children on ECMO. There is, therefore, a risk of inadequate drug levels when using standard dosing.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers analyzed data from 361 infants with confirmed pertussis, finding that 32 (9%) developed fulminant symptoms, which were more common in neonates, unvaccinated, and premature infants.
- * Results indicated that B. pertussis strains that produced PRN were associated with higher risks of fulminant pertussis, suggesting the significance of PRN in the severity of the disease.
Article Synopsis
- The human immune system continues to develop for several years after birth, affecting how young children respond to infections, such as SARS-CoV-2.
- Researchers studied T cell responses in children and adults before, during, and after SARS-CoV-2 infection, revealing that younger children (under 5) had a weaker CD4 T cell response compared to older children and adults with mild disease.
- Following infection, preschool-age children produced similar neutralizing antibodies to adults but had different T cell characteristics and fewer memory B cells, indicating a gradual maturation of their adaptive immune responses.
Article Synopsis
- Respiratory syncytial virus (RSV) causes bronchiolitis in infants, and the monoclonal antibody nirsevimab was approved in the EU in 2022, leading to a national immunisation campaign in France starting September 2023.
- A study was conducted in Paris to evaluate nirsevimab's effectiveness in reducing emergency department visits and hospitalisations for bronchiolitis among infants aged 12 months or younger during the RSV season of 2023-24.
- Out of 2786 infants studied, those who received nirsevimab showed lower rates of emergency visits and hospitalisation for bronchiolitis compared to non-vaccinated infants, but data showed that the majority of those
Article Synopsis
- RSV is a major cause of bronchiolitis, leading to 3 million hospitalizations each year, and nirsevimab is a monoclonal antibody aimed at preventing severe RSV cases in infants.
- A study compared infants hospitalized for RSV bronchiolitis with those visiting for unrelated reasons, assessing nirsevimab’s effectiveness in preventing hospitalizations in those under 12 months old.
- Findings showed nirsevimab reduced hospitalization rates for RSV-associated bronchiolitis by 83% and critical care needs by about 70%, indicating it is an effective treatment option for vulnerable infants.